Published by the Iranian Chemical Society www.orgchemres.org

Org. Chem. Res., Vol. 7, No. 2, 176-189, July 2021.
DOI: 10.22036/org.chem.2023.325681.1273

# Novel Modelling-optimization Approach and Monte Carlo Method on QSAR Study of Bortezomib Drugs 

O. Alizade, R. Sayyadi Kord Abadi* and G. Ghasemi<br>Department of Chemistry and Chemical Engineering, Rasht Branch, Islamic Azad University, Rasht, Iran<br>(Received 20 January 2022, Accepted 22 June 2023)


#### Abstract

Multiple linear regression (MLR) as modeling tool and Imperialist Competitive Algorithm (ICA) as optimization techniques employed to choose the best set of descriptors and The CORAL software has been used as a tool for linear prediction of $-\log \left(\mathrm{IC}_{50}\right)$ (empirical negative logarithm of half of maximal inhibitory concentration) for Bortezomib derivatives. A high predictive ability was observed for the MLR-ICA model with the best number of empires/imperialists ( nEmp ) 90 with root-mean-sum-square errors (RMSE) of 0.0121 and correlation coefficient ( $\mathrm{R}^{2}$ predict) of 0.9896 in gas phase. The 25 data sets were randomly splitted into the training set, the calibration set, the test set in the Monte Carlo method and the number of compounds in the each set ( n ), correlation coefficient ( $\mathrm{R}^{2}$ ), cross-validated correlation coefficient $\left(\mathrm{Q}^{2}\right)$, standard error(s) were calculated $13,0.9826,0.9780,0.161$ in training set; and $\mathrm{n}=6, \mathrm{R}^{2}=0.8463, \mathrm{Q}^{2}=0.7377, \mathrm{~s}=0.715$ in test set in the Threshold (T) of 2 and probe of 3, respectively. From the MLR-ICA method, it was revealed that Espm15u, R5p+, B06 [O-O], $\mathrm{F} 03[\mathrm{~N}-\mathrm{N}], \mathrm{F} 07[\mathrm{C}-\mathrm{O}], \mathrm{MATs} 3 \mathrm{~m}, \mathrm{RDF} 125 \mathrm{v}$ are the most important descriptors. From Monte Carlo simulations, it was found that the presence of double bond and ring, absence of halogens are the most important molecular features affecting the biological activity of the drug. It was concluded that simultaneous utilization of MLR-ICA and Monte Carlo method can lead to a more comprehensive understanding of the relation between physico-chemical, structural or theoretical molecular descriptors of drugs to their biological activities and facilitate designing of new drugs.


Keywords: Bortezomib, QSAR, ICA Algorithm, Monte Carlo method

## INTRODUCTION

Bortezomib is important in the treatment of multiple myeloma that It is also being investigated for the treatment of other hematological malignancies and solid tumors as a single agent or as part of a combined therapy [1-5].

One of the most efficacious approaches for designing new chemical identities and understanding the action mechanisms of drugs is quantitative structure activity relationship (QSAR) [6-9] with several variable selection models including multiple linear regression (MLR), genetic algorithm (GA), simulated annealing algorithm (SA) etc. [10].

Imperialist Competitive Algorithm (ICA) is a new

[^0]population-based optimization algorithm that has recently been introduced for dealing with different kinds of optimization problem [11-14]. The total power of an empire depends on both the power of its colonies and power of the imperialist country because the ICA starts with an initial population called countries and most powerful countries are selected as imperialists and the rest form the colonies of these imperialists and most powerful empires tend to increase their power while weak empires collapse. All empires try to take possession of colonies of other empires and control them [13,15-16].

The CORAL (Correlation And Logic) software with the Monte Carlo method [23-24] was utilized to find simplified molecular input-line entry system (SMILES)-based
descriptors and calculated the correlation weights of the related SMILES [25-27] attributes.

In the present study, multiple linear regressions as linear modeling tool and Imperialist Competitive Algorithm as optimization method and Monte Carlo method were applied to investigate the QSAR in some Bortezomib anticancer drugs.

## COMPUTATIONAL METHODS

## Selection of Descriptors Using MLR-ICA Method

Details of geometry optimizations of compounds were given in our previous work [22]. As it was described, B3lyp/6-311g by Gaussian 09W [17,34] was utilized to optimize the geometries of 25 Bortezomib anti-cancer drugs and Dragon program [35] was used for calculation of 3226 molecular descriptors for each of the 25 compounds [22]. Modeling and optimizing calculations were carried out using Matlab. 2014a [37].

The 776 SPSS [18] screened descriptors [22] were used as the feed to ICA-MLR approach as the population matrix in order to find the best descriptors for the gas phase. The numbers of the most effective descriptors ( 7 for the gas phase) chosen by a stepwise multiple linear regression procedure in our previous work was used as a basis for the number of descriptors in this work.

The employed ICA of this work is depicted in Fig. 1. An efficient ICA algorithm using random points (matrix indices of descriptors) called the initial Countries that are the counterpart of Chromosomes in GA and it is a set of values of a candidate solution for optimization problem.

Empires are sub-populations of countries. Assimilation, which can be considered as a primitive form of Particle Swarm Optimization [19-21] moves all non-best countries (called colonies) in an empire toward the best country (called imperialist) in the same empire to find the colonies with lowest error (RMSE of predicted $-\log$ (IC50) using MLR versus empirical values.

Different number of decision variables (nDes) and different number of empires ( nEmp ) were investigated to obtain the least RMSE and highest $\mathrm{R}^{2}$ using ICA.


Fig. 1. Flowchart of the employed MLR-ICA algorithm.

In ICA-MLR method the number of decision variables ( nDes ) ) and number of empires/imperialists (nEmp) were considered 1 up to 8 in the gas phase and $10,20,30$, respectively.

## MONTE CARLO METHOD

CORAL [33] software was used for calculation of
descriptor correlation weight (DCW) of the 25 Bortezomib compounds with a hybrid optimization scheme including hydrogen-suppressed molecular graph (HSG), hydrogenfilled graphs (HFG) and SMILES representation of molecular structures. Modelling using CORAL software was carried out for thresholds of 1 up to 7 and 100 epochs (i.e., an overall number of 2100 runs were performed). The threshold (T) is a coefficient used to classify SMILES attributes into two groups (1) noise; and (2) active. The threshold that gives desirable statistical quality is denoted by $\mathrm{T}^{*}$. The noise attributes are blocked (their correlation weights are set to zero). Each sequence of computations for finding a new set of modified correlation weights of the model is named an epoch (29). The SMILES-based and Graph -based optimal descriptors are achieved using the following equations [28]:

$$
\begin{align*}
& \mathrm{DCW}(\mathrm{~T}, \mathrm{Nepoch})^{\text {SMILES }}=\alpha \sum \mathrm{CW}(\mathrm{Sk})+\beta \sum \mathrm{CW}(\mathrm{SSk})+ \\
& \gamma \sum \mathrm{CW}(\mathrm{SSSk})+\mathrm{x} . \mathrm{CW}(\mathrm{NOSP})+\mathrm{y} \cdot \mathrm{CW}(\mathrm{HALO})+ \\
& \mathrm{z} . \mathrm{CW}(\mathrm{BOND})  \tag{1}\\
& \mathrm{DCW}(\mathrm{~T}, \mathrm{Nepoch}){ }^{\mathrm{Graph}}=\sum \mathrm{CWAk}+\alpha \sum \mathrm{CW}\left({ }^{0} \mathrm{ECk}\right)+ \\
& \beta \sum \mathrm{CW}\left({ }^{1} \mathrm{ECk}\right)+\gamma \sum \mathrm{CW}\left({ }^{2} \mathrm{ECk}\right)+\delta \sum \mathrm{CW}\left({ }^{3} \mathrm{ECk}\right) \tag{2}
\end{align*}
$$

Where, $\mathrm{S}_{\mathrm{k}}, \mathrm{SS}_{\mathrm{k}}$, and $\mathrm{SSS}_{\mathrm{k}}$ denote one, two, and three component SMILES attributes. The presence or absence of chemical elements are demonstrated by NOSP (nitrogen, oxygen, sulfur, and phosphorus) and HALO (fluorine, chlorine, and bromine). Also "BOND" denotes double ( $=$ ), triple (\#), or stereo chemical bonds (@ or @@). A $\mathrm{A}_{\mathrm{k}}$ in Eq. (2) indicates the occurrence of the $\mathrm{C}, \mathrm{N}, \mathrm{O}$ atoms in the HSG and HFG molecular graphs. The $\alpha, \beta, \gamma$, and $\delta$ coefficients and combinations of their values are used to define various versions of the graph-based optimal descriptor and can be 1 or 0 . The hybrid objective function for finding the optimal descriptors is defined as:

$$
\begin{align*}
& \text { DCW }(T, \text { Nepoch })^{\text {Hybrid }}=\mathrm{DCW}(\mathrm{~T}, \text { Nepoch })^{\text {SMILES }}+ \\
& \text { DCW(T,Nepoch })^{\text {Graph }} \tag{3}
\end{align*}
$$

## RESULTS AND DISCUSSION

## Molecular Descriptors Generation with MLR-ICA Method

All studied Bortezomib compounds (22) have been presented in Fig. 2.

As a first trial, 1000 number of iterations were done to find the most powerful empires and, subsequently, the best descriptors. A plot of the best cost values versus the number of iterations is represented in Fig. 3. It implies that there is no variation in the best cost (MSE) after about 300 iterations. However, in order to ensure that the best descriptors are captured, the number of iterations for the rest of computations was set to 500 .

The effects of number of selected descriptors on the chosen descriptors and the prediction quality (according to $\mathrm{R}^{2}$ and RMSE) was investigated and the results are plotted in Fig. 4. As it is expected, the model's accuracy regarding to $R^{2}$ and RMS increases by increasing the number of model parameters (descriptors in this case).

In order to check the robustness of the selected descriptors by varying the model parameters, the effects of number of empires on them were studied by changing the number of empires from 10 to 20 and 30 .

For choosing the most suitable number of empires, the model was run using different number of empires and 7 number of descriptors (according to our previous work [22]. The results are revealed in Fig. 5. According to these results, the optimum number of empires for the gas phase is 90 .

A plot of the predicted versus empirical values of - $\operatorname{logIC50}$ is depicted Fig. 6. The figure implies that the developed model possesses a high correlation coefficient, indicating that the experimental and predicted values are well correlated. The observed and predicted values of -logIC50 using Matlab program are shown in Table 1.

The last chosen descriptors with $\mathrm{nEmp}=90$ and $\mathrm{nDes}=7$ using MLR-ICA Method have been presented in Table 2 in the gas phase.

## Alizade et al./Org. Chem. Res., Vol. 7, No. 2, 176-189, July 2021.






13



8


14




23
23


Fig. 2. Optimized structure of the compounds used to build QSAR models by B3lyp/6-31g in gas phase [22].


Fig. 3. Plot between Best Cost values compared to the variation of Iteration.


Fig. 4. Effects of number of descriptors on $R^{2}$ and RMS of the model.


Fig. 5. Variation of $R^{2}$ and MSE by varying the number of empires ( $\mathrm{nDes}=7$ ).


Fig. 6. Plot between predicted values compared to Goal with $\mathrm{nDes}=7$ and $\mathrm{nEmp}=90$.

Table 1. Observed and Predicted Values of -logIC50 by Using ICA-MLR

| Predicted | -logIC50 | Predicted | -logIC50 |
| :---: | :---: | :---: | :---: |
| 3.624822 | 3.788 | 0.100947 | 0.304 |
| 1.010875 | 1.01 | 2.021953 | 2.004 |
| 3.773883 | 3.745 | 1.933037 | 1.824 |
| 2.534196 | 2.521 | 1.514501 | 1.721 |
| 0.789456 | 0.801 | 0.191983 | 0.301 |
| 0.737076 | 0.793 | 0.999218 | 1.05 |
| 1.497436 | 1.551 | 0.109389 | 0.22 |
| 0.149343 | -0.037 | 1.005477 | 1.06 |
| -0.13414 | -0.248 | 2.476321 | 2.36 |
| 0.985788 | 0.866 | 0.683296 | 0.456 |
| 1.085169 | 1.156 | 1.5252 | 1.48 |
| 0.914262 | 0.917 | 3.066555 | 2.991 |
| 0.215956 | 0.178 |  |  |

It shows that polarizabilities ( $\mathrm{R} 5 \mathrm{p}+$ ) and Presence/absence of O-O (B06[O-O]), Frequency of N-N(F03[N-N]), Frequency of $\mathrm{C}-\mathrm{O}(\mathrm{F} 03[\mathrm{C}-\mathrm{O}])$, atomic van der Waals volumes (RDF125v), and atomic masses (MATs3m) in the gas phase are important for designing this class of drugs.

The graphs of Espm15u, R5p+, B06 [O-O], F03[N-N], F07[C-O], MATs3m, RDF125v descriptors in the gas phase versus the half maximal inhibitory concentration (IC50) were plotted (Fig. 7).

Table 2. The Best Selected Descriptors Using MLR-ICA Method with $n$ Des $=7$ and $n E m p=90$ in Gas Phase

| Descriptor | Definition | Type |
| :--- | :--- | :---: |
| Espm15u | Spectral moment 15 from edge adjacent matrix | Edge adjacency indices |
| R5p+ | R maximal autocorrelation of lag 5/weighted by atomic polarizabilities | GETAWAY descriptors |
| B06[O-O] | Presence/absence of O-O at topological distance 06 | 2D Binary fingerprints |
| F03[N-N] | Frequency of N-N at topological distance 03 | 2D Frequency fingerprints |
| F03[C-O] | Frequency of C-O at topological distance 07 | 2D Frequency fingerprints |
| MATs3m | Moran autocorrelation-lag3/weighted by atomic masses <br> RDF125vRadial Distribution Function-12.5/Weighted by atomic van der Waals <br> volumes | 2D Autocorrelations |



Fig. 7. Plot between IC50 experimental versus the Espm15u, R5p+, B06[O-O], F03[N-N], F07[C-O], MATs3m, RDF125v descriptors.

The charts in the gas phase show that IC50 value decreases via increasing Espm15u, R5p+ and, MATs3m descriptors and decreasing $\mathrm{B} 06[\mathrm{O}-\mathrm{O}]$, $\mathrm{F} 03[\mathrm{~N}-\mathrm{N}]$, and RDF125v descriptors. As the F07[C-O] descriptor increased from 15 to near 20, no changes in IC50 value was observed. Thus during this period, a bar was seen in the response.

Statistical parameter and QSAR model of the compounds from the previous literatures are presented on the Table 2 [22,6,7,36]. It shows that the results of

ICA-MLR method in this work (Table 3) is better than the other QSAR models in previous studies.

## Result of the Monte Carlo Method

The statistical parameters of the models obtained with molecular graphs (HSG) and SMILES with Eq. (3) are shown in Tables 4-6. The performance of the employed splits were compared with each other by the criterion of the predictability $\left(\mathrm{Rm}^{2}\right)$ in test set which should be larger than 0.5 [30] and correlation coefficient ( $\mathrm{R}^{2}$ ) in each set, crossvalidated correlation coefficient ( $\mathrm{Q}^{2}$ ), standard error of estimation (s), Fischer F-ratio (F). The criterion of the predictability $\left(\mathrm{Rm}^{2}\right)$ is mean of $\mathrm{R}^{2} m$ and $R^{12} m$ values in test set.

Table 3. Statical Parameter and QSAR Model from the Previous Literatures

| Compounds | QSAR model | Statistical parameters |
| :--- | :---: | :---: |
| Sulfonamide derivatives | GA-ANN | $\mathrm{R}^{2}$ pred $=0.9894$ |
| BORTEZOMIB derivatives | GA-ANN | $\mathrm{R}^{2}$ pred $=0.9728$ |
| Taxol derivatives | GA-ANN | $\mathrm{R}^{2}$ pred $=0.82$ |
| Several etoposides | GA-ANN | $\mathrm{R}^{2}$ pred $=0.966$ |

Table 4. The Split Models in Monte Carlo Method


Alizade et al./Org. Chem. Res., Vol. 7, No. 2, 176-189, July 2021.

Table 5. Statistical Data Calculated with Both HSG, HFG and SMILES for Three Random Splits into Test Set. Best Model are Indicated by Bold

| Threshold | $\mathrm{R}^{2}$ test <br> Probe 1 | $\mathrm{R}^{2}$ test <br> Probe 2 | $\mathrm{R}^{2}$ test <br> Probe 3 | $\mathrm{R}^{2}$ test <br> Average | Dispersion |
| :---: | :---: | :---: | :---: | :---: | :---: |
| SPLIT 1 |  |  |  |  |  |
| 1 | 0.7366 | 0.7267 | 0.7153 | 0.7262 | 0.0087 |
| 2 | 0.8160 | 0.8201 | 0.8471 | 0.8277 | 0.0138 |
| 3 | 0.7507 | 0.7407 | 0.7493 | 0.7469 | 0.0044 |
| 4 | 0.7502 | 0.7545 | 0.7419 | 0.7488 | 0.0052 |
| 5 | 0.6698 | 0.6874 | 0.6993 | 0.6855 | 0.0121 |
| 6 | 0.6260 | 0.6341 | 0.5799 | 0.6133 | 0.0239 |
| 7 | 0.6183 | 0.6185 | 0.6064 | 0.6144 | 0.0057 |
| SPLIT2 |  |  |  |  |  |
| 1 | 0.8015 | 0.7756 | 0.7981 | 0.7917 | 0.0115 |
| 2 | 0.8223 | 0.8292 | 0.8339 | 0.8285 | 0.0048 |
| 3 | 0.6503 | 0.6799 | 0.6732 | 0.6678 | 0.0126 |
| 4 | 0.7769 | 0.8002 | 0.7882 | 0.7884 | 0.0095 |
| 5 | 0.8150 | 0.8060 | 0.8199 | 0.8136 | 0.0057 |
| 6 | 0.5296 | 0.5164 | 0.4975 | 0.5145 | 0.0132 |
| 7 | 0.5303 | 0.4826 | 0.5048 | 0.5059 | 0.0195 |
| SPLIT3 |  |  |  |  |  |
| Continue Table 4 |  |  |  |  |  |
| 1 | 0.6166 | 0.6160 | 0.6176 | 0.6168 | 0.0007 |
| 2 | 0.7764 | 0.7760 | 0.7760 | 0.7762 | 0.0002 |
| 3 | 0.6654 | 0.6636 | 0.6939 | 0.6743 | 0.0139 |
| 4 | 0.6557 | 0.6636 | 0.6683 | 0.6625 | 0.0052 |
| 5 | 0.6394 | 0.6417 | 0.6573 | 0.6462 | 0.0079 |
| 6 | 0.6443 | 0.6633 | 0.6478 | 0.6518 | 0.0083 |
| 7 | 0.6102 | 0.6091 | 0.6097 | 0.6097 | 0.0004 |

The results of the splits proved that split 1 with threshold and probe equal 2,3 (Tables $3,4,5$ ), were better than other splits because this model have good predictability according to criterion $\mathrm{R}^{2} \mathrm{~m}[30,32]$ which should be larger than 0.5 .

The given experimental and predicted in Table 7 are plotted against each other in Fig. 8. A good correlation between the calculated and empirical values of -log IC50 can be observed in this figure that approves the appropriateness of the developed model.

The variation of correlation coefficient (test set) with
respect to threshold and the number of epochs are plotted in Figs. 9A, 9B. Figure 9A show that with increase in threshold, the correlation coefficient between experimental and calculated values of endpoint for training and test set were reduced and in threshold equai 2 value correlation coefficient for test set has a maximum. In addition, as the number of epochs of the Monte Carlo method optimization increased, the correlation coefficient for the training and calibration and test sets, were increased as well (Fig. 9B).

Table 6. Statistical Quality of Models Calculated with Both HSG, HFG and SMILES for Training, Calibration and Test Sets in Threshold and Probe Equal 2 and 1-3, Respectively. Best Model are Indicated by Bold

| Threshold-probe | $\mathrm{R}^{2}$ | $\mathrm{Q}^{2}$ | S | $\mathrm{R}^{2} \mathrm{~m} \text { TEST [31] }$ | $\mathrm{R} *{ }^{2} \mathrm{~m} \text { TEST [30] }$ | ARmTEST [32] |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  | Should be $>0.5$ | Should be $>0.5$ | Should be $<0.2$ |
| 2-1 | 0.9855 | 0.9818 | 0.147 |  |  |  |
| Training ( $\mathrm{n}=13$ ) |  |  |  |  |  |  |
| $\text { Calib }(\mathrm{n}=6)$ | 0.9997 | 0.9991 | 0.978 |  |  |  |
| Test ( $\mathrm{n}=6$ ) | 0.8154 | 0.6739 | 0.814 | 0.6613 | 0.7982 | 0.1369 |
| 2-2 | 0.9844 | $0.9802$ | 0.153 |  |  |  |
| Training ( $\mathrm{n}=13$ ) |  |  |  |  |  |  |
| Calib ( $\mathrm{n}=6$ ) | 0.9998 | 0.9996 | 0.965 |  |  |  |
| Test ( $\mathrm{n}=6$ ) | 0.8193 | 0.7071 | $0.7071$ | 0.6782 | 0.8107 | 0.1325 |
| 2-3 | 0.9826 | 0.9780 | 0.161 |  |  |  |
| Training ( $\mathrm{n}=13$ ) |  |  |  |  |  |  |
| Calib ( $\mathrm{n}=6$ ) | 0.9998 | 0.9995 | 0.987 |  |  |  |
| Test ( $\mathrm{n}=6$ ) | 0.8463 | 0.7377 | 0.715 | 0.6699 | 0.7943 | 0.1244 |



Fig. 8. Correlation between experimental and predicted -logIC50 calculated using Eq. (3).

Figure 9D show the correlation coefficient for the test set in the Threshold 1-5 and Nepoch (denoted $\mathrm{N}^{*}$ ) 1-100. It indicate that in Nepoch 80 the correlation coefficient for the test set is maximum.

The distribution of SMILES notations in the train, calibration and test sets are reported in Table 8.

Molecular features are sorted according to their correlation weights and are given in Table 9. Molecular feature with negative correlation weights are omitted due to their inverse effect on the - logIC50 value. The higher the correlation weigh of a molecular feature, the lower the value of IC50, therefore, the feature is more significant. Definitions of the molecular features are given in Table 9.

Thus according to Table 10, presence of ring, absence of halogens, presence of double bond, present B element, present of F element, presence of nitrogen and oxygen together with absent sulfur and phosphorus, branch in molecular skeleton with B, F elements are increases of the - $\log$ IC50 and the half maximal inhibitory concentration (IC50) value decreases. Thus this work predicts in new design for this class of drugs, the presence or absence of these contradictions should be considered.

Table 7. Calculated Values for DCW, the Experimental Activity Data (-log IC50) and Calculated Values for - $\log$ IC50 with Application of CORAL in Split1 $(\mathrm{T}=2)$

| Compound | Set | DCW | Exp. | Calc. |
| :---: | :---: | :---: | :---: | :---: |
| 1 | Train | 82.40971 | 3.788 | 3.7416 |
| 2 | Train | 66.51002 | 1.01 | 0.7211 |
| 3 | Train | 82.40971 | 3.745 | 3.7416 |
| 5 | Train | 67.79072 | 0.801 | 0.9644 |
| 9 | Train | 62.29971 | -0.248 | -0.0788 |
| 11 | Train | 68.75969 | 1.156 | 1.1484 |
| 12 | Train | 65.90575 | 0.917 | 0.6063 |
| 13 | Train | 63.62701 | 0.178 | 0.1734 |
| 14 | Train | 64.34652 | 0.304 | 0.3101 |
| 15 | Train | 73.17845 | 2.004 | 1.9879 |
| 17 | Train | 71.55459 | 1.721 | 1.6794 |
| 21 | Train | 69.40098 | 1.06 | 1.2703 |
| 24 | Train | 71.40293 | 1.48 | 1.6506 |
| 6 | Calib | 68.45861 | 0.793 | 1.0912 |
| 10 | Calib | 68.47977 | 0.866 | 1.0953 |
| 18 | Calib | 68.13753 | 0.301 | 1.0302 |
| 22 | Calib | 69.45434 | 2.36 | 2.011 |
| 23 | Calib | 68.23210 | 0.456 | 1.0482 |
| 25 | Calib | 69.83551 | 2.991 | 2.302 |
| 4 | Test | 80.15323 | 2.521 | 3.01 |
| 7 | Test | 76.00969 | 1.551 | 2.03 |
| 8 | Test | 62.29971 | -0.037 | -0.0788 |
| 16 | Test | 72.04633 | 1.824 | 1.7728 |
| 19 | Test | 70.14340 | 1.05 | 1.4113 |
| 20 | Test | 68.71192 | 0.22 | 1.1394 |



Fig. 9. The variation of correlation coefficient for test set by threshold and number of epochs. (A): effects of threshold. (B) Effects of the number of epochs. (C) 3-D surface plot of $\mathrm{R}^{2}$ according to the threshold and the number of epochs. (D) Contour plots of $\mathrm{R}^{2}$ according to the threshold and the number of epochs.

Table 8. SMILES Notations 25 Compound of Bortozomib and Train, Calibration and Test Set

| Compound | SMILES | Set |
| :---: | :---: | :---: |
| 1 | $\mathrm{CC}(\mathrm{C}) \mathrm{CC}(\mathrm{NC}(=\mathrm{O}) \mathrm{C}(\mathrm{CC} 1=\mathrm{CC}=\mathrm{CC}=\mathrm{C} 1) \mathrm{NC}(=\mathrm{O}) \mathrm{C} 2=\mathrm{NC}=\mathrm{CN}=\mathrm{C} 2) \mathrm{B}(\mathrm{O}) \mathrm{O}$ | Train |
| 2 | $\mathrm{OB}(\mathrm{O}) \mathrm{C}(\mathrm{CC} 1=\mathrm{CC}=\mathrm{C}(\mathrm{F}) \mathrm{C}=\mathrm{C} 1) \mathrm{NC}(=\mathrm{O}) \mathrm{C}(\mathrm{CC} 2=\mathrm{CC}=\mathrm{CC}=\mathrm{C} 2) \mathrm{NC}(=\mathrm{O}) \mathrm{C} 3=\mathrm{NC}=\mathrm{CN}=\mathrm{C} 3$ | Train |
| 3 | $\mathrm{CC}(\mathrm{C}) \mathrm{CC}(\mathrm{NC}(=\mathrm{O}) \mathrm{CC}(\mathrm{NC}(=\mathrm{O}) \mathrm{C} 1=\mathrm{NC}=\mathrm{CN}=\mathrm{C} 1) \mathrm{C} 2=\mathrm{CC}=\mathrm{CC}=\mathrm{C} 2) \mathrm{B}(\mathrm{O}) \mathrm{O}$ | Train |
| 5 | $\mathrm{CC}(\mathrm{C}) \mathrm{CC}(\mathrm{NC}(=\mathrm{O}) \mathrm{CC}(\mathrm{NC}(=\mathrm{O}) \mathrm{C} 1=\mathrm{NC}=\mathrm{CN}=\mathrm{C} 1) \mathrm{C} 2=\mathrm{CC}=\mathrm{C}(\mathrm{Cl}) \mathrm{C}=\mathrm{C} 2) \mathrm{B}(\mathrm{O}) \mathrm{O}$ | Train |
| 9 | $\mathrm{CC}(\mathrm{C}) \mathrm{CC}(\mathrm{NC}(=\mathrm{O}) \mathrm{C}(\mathrm{CC}(\mathrm{C}) \mathrm{C}) \mathrm{NC}(=\mathrm{O}) \mathrm{C}(\mathrm{CCl}=\mathrm{CC} 2=\mathrm{CC}=\mathrm{CC}=\mathrm{C} 2 \mathrm{C}=\mathrm{C} 1) \mathrm{NC}(=\mathrm{O}) \mathrm{C} 3=\mathrm{NC}=\mathrm{CN}=$ | Train |
|  | $\mathrm{C} 3) \mathrm{B}(\mathrm{O}) \mathrm{O}$ |  |
| 11 | $\mathrm{COC} 1=\mathrm{CC}=\mathrm{C}(\mathrm{C}=\mathrm{C} 1) \mathrm{C}(\mathrm{CC}(=\mathrm{O}) \mathrm{NC}(\mathrm{CC}(\mathrm{C}) \mathrm{C}) \mathrm{B}(\mathrm{O}) \mathrm{O}) \mathrm{NC}(=\mathrm{O}) \mathrm{C} 2=\mathrm{CC}=\mathrm{CC}=\mathrm{C} 2$ | Train |
| 12 | $\mathrm{CC}(\mathrm{C}) \mathrm{CC}(\mathrm{NC}(=\mathrm{O}) \mathrm{C}(\mathrm{CC} 1=\mathrm{CC} 2=\mathrm{CC}=\mathrm{CC}=\mathrm{C} 2 \mathrm{C}=\mathrm{C} 1) \mathrm{NC}(=\mathrm{O}) \mathrm{C} 3=\mathrm{NC}=\mathrm{CN}=\mathrm{C} 3) \mathrm{B}(\mathrm{O}) \mathrm{O}$ | Train |
| 13 | $\mathrm{CC}(\mathrm{C}) \mathrm{CC}(\mathrm{NC}(=\mathrm{O}) \mathrm{CC}(\mathrm{NC}(=\mathrm{O}) \mathrm{CC} 1 \mathrm{CCCC} 2=\mathrm{C} 1 \mathrm{C}=\mathrm{CC}=\mathrm{C} 2) \mathrm{C} 3=\mathrm{CC}(=\mathrm{CC}=\mathrm{C} 3) \mathrm{F}) \mathrm{B}(\mathrm{O}) \mathrm{O}$ | Train |
| 14 | $\mathrm{CC}(\mathrm{C}) \mathrm{CC}(\mathrm{NC}(=\mathrm{O}) \mathrm{CC}(\mathrm{NC}(=\mathrm{O}) \mathrm{C} 1 \mathrm{CCCCC} 1) \mathrm{C} 2=\mathrm{CC}(=\mathrm{CC}=\mathrm{C} 2) \mathrm{F}) \mathrm{B}(\mathrm{O}) \mathrm{O}$ | Train |
| 15 | $\mathrm{CC}(\mathrm{C}) \mathrm{CC}(\mathrm{NC}(=\mathrm{O}) \mathrm{CC}(\mathrm{NC}(=\mathrm{O}) \mathrm{C} 1=\mathrm{CC} 2=\mathrm{CC}=\mathrm{CC}=\mathrm{C} 2 \mathrm{C}=\mathrm{C} 1) \mathrm{C} 3=\mathrm{CC}=\mathrm{CC}(=\mathrm{C} 3) \mathrm{F}) \mathrm{B}(\mathrm{O}) \mathrm{O}$ | Train |
| 17 | $\mathrm{COC} 1=\mathrm{CC}=\mathrm{C}(\mathrm{C}=\mathrm{C} 1) \mathrm{C}(\mathrm{CC}(=\mathrm{O}) \mathrm{NC}(\mathrm{CC}(\mathrm{C}) \mathrm{C}) \mathrm{B}(\mathrm{O}) \mathrm{O}) \mathrm{NC}(=\mathrm{O}) \mathrm{C} 2=\mathrm{CC} 3=\mathrm{C}(\mathrm{CCCC} 3) \mathrm{C}=\mathrm{C} 2$ | Train |
| 21 | $\mathrm{COC} 1=\mathrm{CC}(=\mathrm{CC}=\mathrm{C} 1) \mathrm{C}(\mathrm{CC}(=\mathrm{O}) \mathrm{NC}(\mathrm{CC}(\mathrm{C}) \mathrm{C}) \mathrm{B}(\mathrm{O}) \mathrm{O}) \mathrm{NC}(=\mathrm{O}) \mathrm{C} 2=\mathrm{CC}=\mathrm{CN}=\mathrm{C} 2$ | Train |
| 24 | $\mathrm{COC} 1=\mathrm{CC}(=\mathrm{CC}=\mathrm{C} 1) \mathrm{C}(\mathrm{CC}(=\mathrm{O}) \mathrm{NC}(\mathrm{CC} 2=\mathrm{CC}=\mathrm{CC}=\mathrm{C} 2) \mathrm{B}(\mathrm{O}) \mathrm{O}) \mathrm{NC}(=\mathrm{O}) \mathrm{C} 3=\mathrm{CN}=\mathrm{CC}=\mathrm{C} 3$ | Train |
| 6 | $\mathrm{OB}(\mathrm{O}) \mathrm{C}(\mathrm{CC} 1=\mathrm{CC}=\mathrm{CC}=\mathrm{C} 1) \mathrm{NC}(=\mathrm{O}) \mathrm{CC}(\mathrm{NC}(=\mathrm{O}) \mathrm{C} 2=\mathrm{NC}=\mathrm{CN}=\mathrm{C} 2) \mathrm{C} 3=\mathrm{CC}=\mathrm{CC}=\mathrm{C} 3$ | Calib |
| 10 | $\mathrm{CC}(\mathrm{C}) \mathrm{CC}(\mathrm{NC}(=\mathrm{O}) \mathrm{CC}(\mathrm{NC}(=\mathrm{O}) \mathrm{C} 1=\mathrm{NC}=\mathrm{CN}=\mathrm{C} 1) \mathrm{C} 2=\mathrm{CC}=\mathrm{CC}(=\mathrm{C} 2) \mathrm{Cl}) \mathrm{B}(\mathrm{O}) \mathrm{O}$ | Calib |
| 18 | $\mathrm{COC} 1=\mathrm{CC}(=\mathrm{CC}=\mathrm{C} 1) \mathrm{C}(\mathrm{CC}(=\mathrm{O}) \mathrm{NC}(\mathrm{CC}(\mathrm{C}) \mathrm{C}) \mathrm{B}(\mathrm{O}) \mathrm{O}) \mathrm{NC}(=\mathrm{O}) \mathrm{CC} 2 \mathrm{CCC} 3=\mathrm{C}(\mathrm{C} 2) \mathrm{C}=\mathrm{CC}=\mathrm{C} 3$ | Calib |
| 22 | $\mathrm{COC} 1=\mathrm{CC}(=\mathrm{CC}=\mathrm{C} 1) \mathrm{C}(\mathrm{CC}(=\mathrm{O}) \mathrm{NC}(\mathrm{CC} 2=\mathrm{C}(\mathrm{F}) \mathrm{C}=\mathrm{CC}=\mathrm{C} 2) \mathrm{B}(\mathrm{O}) \mathrm{O}) \mathrm{NC}(=\mathrm{O}) \mathrm{C} 3=\mathrm{CN}=\mathrm{CC}=\mathrm{C} 3$ | Calib |
| 23 | $\mathrm{COC} 1=\mathrm{CC}=\mathrm{C}(\mathrm{CC}(\mathrm{NC}(=\mathrm{O}) \mathrm{C}(\mathrm{NC}(=\mathrm{O}) \mathrm{C}(\mathrm{CC} 2=\mathrm{CC}=\mathrm{C}(\mathrm{OC}) \mathrm{C}=\mathrm{C} 2) \mathrm{NC}(=\mathrm{O}) \mathrm{C} 3=\mathrm{CC}=\mathrm{CN}=\mathrm{C} 3) \mathrm{C}(\mathrm{C})$ | Calib |
|  | C) $\mathrm{B}(\mathrm{O}) \mathrm{O}) \mathrm{C}=\mathrm{C} 1 \sim$ |  |
| 25 | $\mathrm{COC} 1=\mathrm{CC}=\mathrm{CC}(=\mathrm{C} 1) \mathrm{C}(\mathrm{CC}(=\mathrm{O}) \mathrm{NC}(\mathrm{CC} 2=\mathrm{CC}(=\mathrm{CC}=\mathrm{C} 2) \mathrm{C}) \mathrm{B}(\mathrm{O}) \mathrm{O}) \mathrm{NC}(=\mathrm{O}) \mathrm{C} 3=\mathrm{CC}=\mathrm{CN}=\mathrm{C} 3$ | Calib |
| 4 | $\mathrm{CC}(\mathrm{C}) \mathrm{CC}(\mathrm{NC}(=\mathrm{O}) \mathrm{CC}(\mathrm{NC}(=\mathrm{O}) \mathrm{C} 1=\mathrm{NC}=\mathrm{CN}=\mathrm{C} 1) \mathrm{C} 2=\mathrm{CC}=\mathrm{C}(\mathrm{C}) \mathrm{C}=\mathrm{C} 2) \mathrm{B}(\mathrm{O}) \mathrm{O}$ | Test |
| 7 | $\mathrm{CC} 1=\mathrm{CC}=\mathrm{C}(\mathrm{CC}(\mathrm{NC}(=\mathrm{O}) \mathrm{CC}(\mathrm{NC}(=\mathrm{O}) \mathrm{C} 2=\mathrm{NC}=\mathrm{CN}=\mathrm{C} 2) \mathrm{C} 3=\mathrm{CC}=\mathrm{CC}=\mathrm{C} 3) \mathrm{B}(\mathrm{O}) \mathrm{O}) \mathrm{C}=\mathrm{C} 1$ | Test |
| 8 | $\mathrm{CC}(\mathrm{C}) \mathrm{CC}(\mathrm{NC}(=\mathrm{O}) \mathrm{C}(\mathrm{CC} 1=\mathrm{CC}=\mathrm{C} 2 \mathrm{C}=\mathrm{CC}=\mathrm{CC} 2=\mathrm{C} 1) \mathrm{NC}(=\mathrm{O}) \mathrm{C}(\mathrm{CC}(\mathrm{C}) \mathrm{C}) \mathrm{NC}(=\mathrm{O}) \mathrm{C} 3=\mathrm{NC}=\mathrm{CN}=$ | Test |
|  | $\mathrm{C} 3) \mathrm{B}(\mathrm{O}) \mathrm{O}$ |  |
| 16 | $\mathrm{COC} 1=\mathrm{CC}(=\mathrm{CC}=\mathrm{C} 1) \mathrm{C}(\mathrm{CC}(=\mathrm{O}) \mathrm{NC}(\mathrm{CC}(\mathrm{C}) \mathrm{C}) \mathrm{B}(\mathrm{O}) \mathrm{O}) \mathrm{NC}(=\mathrm{O}) \mathrm{CC} 2=\mathrm{CC} 3=\mathrm{C}(\mathrm{CCCC} 3) \mathrm{C}=\mathrm{C} 2$ | Test |
| 19 | $\mathrm{COC} 1=\mathrm{CC}=\mathrm{CC}(=\mathrm{C} 1) \mathrm{C}(\mathrm{CC}(=\mathrm{O}) \mathrm{NC}(\mathrm{CC} 2=\mathrm{CC}=\mathrm{CC}(=\mathrm{C} 2) \mathrm{F}) \mathrm{B}(\mathrm{O}) \mathrm{O}) \mathrm{NC}(=\mathrm{O}) \mathrm{C} 3=\mathrm{CC}=\mathrm{CN}=\mathrm{C} 3$ | Test |
| 20 | $\mathrm{COC} 1=\mathrm{C}(\mathrm{C}=\mathrm{CC}=\mathrm{C} 1) \mathrm{C}(\mathrm{CC}(=\mathrm{O}) \mathrm{NC}(\mathrm{CC}(\mathrm{C}) \mathrm{C}) \mathrm{B}(\mathrm{O}) \mathrm{O}) \mathrm{NC}(=\mathrm{O}) \mathrm{C} 2=\mathrm{CC}=\mathrm{CN}=\mathrm{C} 2$ | Test |

Table 9. SMILES Attributes with Positive Correlation Weights for Split 1

| SMILES attributes | CWs | SMILES attributes | CWs |
| :--- | :---: | :--- | :---: |
| $=\ldots 1 \ldots \ldots$. | 12.35152 | $=\ldots(\ldots \ldots$. | 1.96591 |
| HALO00000000 | 10.68296 | EC0-C...4... | 1.91069 |
| $2 \ldots(\ldots \ldots$. | 10.60929 | O... $=\ldots \ldots$. | 1.88524 |
| $=\ldots 2 \ldots \ldots$. | 7.17354 | EC0-F...1... | 1.83472 |
| $3 \ldots(\ldots \ldots$. | 6.75474 | O...C....... | 1.78698 |
| EC0-B...3... | 6.7398 | F.......... | 1.74197 |
| $1 \ldots \ldots \ldots$. | 6.42055 | C... $=\ldots \ldots$. | 1.66038 |
| C6.......... | 6.22602 | N...(...... | 1.17831 |
| B...(...... | 6.1294 | C...C...... | 1.0846 |
| NOSP11000000 | 5.6663 | EC0-N...3... | 0.83306 |
| $2 \ldots \ldots \ldots .$. | 5.19031 | EC0-N...2... | 0.71064 |
| C6....H.2... | 4.99018 | C...(...... | 0.70107 |
| B.......... | 4.93344 | N... $=\ldots \ldots$. | 0.67825 |
| BOND10000000 | 4.45183 | EC0-O...2... | 0.48824 |
| $1 \ldots(\ldots \ldots .$. | 2.52393 | N...C...... | 0.43716 |
| F.......... | 2.46682 | O...(...... | 0.23297 |
| EC0-O...1... | 2.27044 | EC0-C...3... | 0.19768 |

Table 10. Definition of the SMILES Attributes

| SMILES attributes | Comment |
| :--- | :--- |
| HALO 00000000 | Absence of $\mathrm{F}, \mathrm{Cl}, \mathrm{Br}$ |
| $\mathrm{C} \ldots \mathrm{C} \ldots \ldots .$. | Presence of carbon-carbon bonds $(\mathrm{sp} 3)$ |
| $\mathrm{C} \ldots(\ldots \mathrm{C} \ldots$ | SP3 Carbon atoms with branching |
| $++++\mathrm{O}--\mathrm{B} 2==$ | Presence of oxygen and double bonds |
| $\mathrm{C} \ldots=\ldots \ldots$. | SP2 Carbon atom |
| $(\ldots \ldots \ldots .$. | Branching in molecular skeleton |
| $\mathrm{O} \ldots \ldots \ldots \ldots$ | Presence of oxygen |
| $1 \ldots \ldots \ldots .$. | Presence of rings |
| $++++\mathrm{N}-\ldots-\mathrm{B} 2==$ | Presence of nitrogen and double bond |
| $=$ | Double bond |
| @ | Stereo specific bond |
| $\#$ | Triplet bond |

## CONCLUSIONS

In this study, MLR-ICA and Monte Carlo investigations were used to study the structure-activity relationships of 25 Bortezomib Anticancer Drugs. The best descriptors with ICA and $\mathrm{nEmp}=90$ proved that Espm15u, R5p+, B06[O-O], F03[N-N], F07[C-O], MATs3m, RDF125v descriptors in the gas phase were more significant than other descriptors to create QSAR model and predict biological activity of Bortezomib substitution patterns.

Noting that the aforementioned descriptors are the most effective descriptors in MLR-ICA methods, atomic polarizabilities and atomic masses should be maximized and absence of O-O, Frequency of $\mathrm{N}-\mathrm{N}$, atomic van der Waals volumes should be minimized in designing new drugs
The biological activity of the Bortezomib inhibition was predicted with tree random splits into the sub-training, calibration, and test sets in the Monte Carlo method. The best results were obtained in split 1 with $n=6, R^{2}=0.8463$, $\mathrm{Q}^{2}=0.7377, \mathrm{~s}=0.715$ in test set and by both molecular graph (HSG) and SMILES.

Monte Carlo method revealed that presence of B element, presence of nitrogen and oxygen together with absent sulfur and phosphorus are the most important molecular features

The most important physicochemical and structural descriptors were presented and discussed. It was concluded that the simultaneous use of Monte Carlo and linear and nonlinear methods gives deeper and more comprehensive knowledge about the effects of molecular and structural descriptors on the activity of drugs and provides better insights to design new drugs.

## ACKNOWLEDGEMENT

The support of Rasht Branch Islamic Azad University, is gratefully acknowledged.

## REFERENCES

[1] M.A. Gertz, Am. J. Hematol. 93 (2018) 1169.
[2] R.C. Kane, A.T. Farrell, R. Sridhara, R. Pazdur, Clin. Cancer Res. 12 (2006) 2955.
[3] Q.P. Dou, R.H. Goldfarb, Idrugs. 5 (2002) 828.
[4] R.I. Fisher, S.H. Kahl Bernstein, B.S.B. Djulbegovic, M.J. Robertson, S. de Vos, E. Epner, A. Krishnan, J.P. Leonard, S. Lonial, E.A. Stadtmauer, O.A. O'Connor, H. Shi, A.L. Boral, A. Goy, J. Clin. Oncol. 24 (2006) 4867.
[5] C.N. Papandreou, D.D. Daliani, D. Nix, H. Yang, T. Madden, X. Wang, C.S. Pien, R.E. Millikan, L. Pagliaro, J. Kim, J. Adams, P. Elliott, D. Esseltine, A. Petrusich, P. Dieringer, C. Perez, CJ. Logothetis. J. Clin. Oncol. 22 (2004) 2108.
[6] R. SayyadikordAbadi, A. Alizadehdakhel, Rev. Roum. Chim. 63 (2018) 171.
[7] R. SayyadikordAbadi, A. Alizadehdakhel, S. Tajadodi Paskiabei, J. Korean Chem. Soci. 60 (2016) 225.
[8] V.K. Gupta, D. Dina Brauneis, A.C. Shelton, K. Quillen, S. Sarosiek, J.M. Sloan, V. Sanchorawala, Biology of Blood and Marrow Transplant. 25 (2019) e169.
[9] H.K. Srivastava, F.A. Pasha, P.P. Singh, Int. J. Quantum. Chem. 103 (2005) 237.
[10] V.R. Consonni, M. Todeschini, M. Pavan, J. Chem. Inf. Comput. Sci. 42 (2002) 693.
[11] T. Niknam, E. Taherian Fard, N. Pourjafarian, A. Rousta. Eng. Appl. Artif. Intell. 24 (2011) 306.
[12] S. Hosseini, A. Al Khaled, Appl. Soft Comput. 24 (2014) 1078.
[13] E. Shokrollahpour, M. Zandieh, B. Dorri, Int. J. Prod. Res. 49 (2011) 3087.
[14] M. Bagher, M. Zandieh, H. Farsijani, Int. J. Adv. Manuf. Tech. 54 (2011) 271.
[15] S.J. Mousavi Rad, T.F. Akhlaghian, K. Mollazade, Int. J. Comput. Appl. 40 (2012) 41.
[16] S. Karami, S.B. Shokouhi, Int. J. Comput. Theory Eng. 4 (2012) 137.
[17] D. Horvath, B. Mao, Molecular Informatics 22 (2003) 498.
[18] S. Putta, J. Eksterowicz, C. Lemmen, R. Stanton, J. Chem. Inf. Comput. Sci. 43 (2003) 1623.
[19] E. Atashpaz-Gargari, C. Lucas, Imperialist competitive algorithm: An algorithm for optimization inspired by imperialistic competition. In IEEE Congress on

Evolutionary Computation. Singapore (2007) 661.
[20] E.A. Gargari, F. Hashemzadeh, R. Rajabioun, C. Lucas, Int. J. Intell. Comput. Cybern. 1 (2008) 337.
[21] J.-L. Lin, Y.-H. Tsai, C.-Y. Yu, M.-S. Li, Algorithms 5 (2012) 433.
[22] R. SayyadikordAbadi, A. Alizadehdakhel, Rev. Roum. Chim. 63 (2018) 931.
[23] A.P. Toropova, A.A. Toropov, E. Benfenati, G. Gini, D. Leszczynska, J. Leszczynski, J. Comput. Chem. 32 (2011) 2727.
[24] A.A. Toropov, A.P. Toropova, S.E. Martyanov, E. Benfenati, G. Gini, D. Leszczynska, J. Leszczynski, Chemom. Intell. Lab. 109 (2011) 94.
[25] D. Weininger, J. Chem. Inf. Comput. Sci. 28 (1988) 31.
[26] D. Weininger, A. Weininger, J.L. Weininger, J. Chem. Inf. Comput. Sci. 29 (1989) 97.
[27] D. Weininger, J. Chem. Inf. Comput. Sci. 30 (1990) 237.
[28] J. Veselinović, A. Veselinović, A. Toropov, A. Toropova, I. Damnjanović, G. Nikolić, Scientific Journal of the Faculty of Medicine in Niš 31 (2014) 95.
[29] A.M. Veselinović, J.B. Milosavljević, A.A. Toropov, G.M. Nikolić, Eur. J. Pharm. Sci. 48 (2013) 3.
[30] A. Golbraikh, A. Tropsha, J. Mol. Graph. Model. 20 (2002) 269.
[31] A.A. Toropov, A.P. Toropova, E. Emilio Benfenati, Chem. Biol. Drug Des. 73 (2009) 442.
[32] P.K. Ojha, I. Mitra, R.N. Das, K. Roy, Chemometr. Intell.

Lab. 107 (2011) 194.
[33] http://www.insilico.eu/coral/.
[34] M.J. Frisch, G.W. Trucks, H. B. Schlegel, G. E. Scuseria, M.A. Robb, J.R. Cheeseman, G. Scalmani, V. Barone, B. Mennucci, G.A. Petersson, H. Nakatsuji, M. Caricato, X. Li, H.P. Hratchian, A.F. Izmaylov, J. Bloino, G. Zheng, J.L. Sonnenberg, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, J.A. Montgomery, J.E. Peralta, F. Ogliaro, M. Bearpark, J.J. Heyd, E. Brothers, K.N. Kudin, V.N. Staroverov, R. Kobayashi, J. Normand, K. Raghavachari, A. Rendell, J. C. Burant, S.S. Iyengar, J. Tomasi, M. Cossi, N. Rega, J. M. Millam, M. Klene, J.E. Knox, J.B. Cross, V.C. Bakken, C. Adamo, J. Jaramillo, R. Gomperts, R. E. Stratmann, O. Yazyev, A.J. Austin, R. Cammi, C. Pomelli, J.W. Ochterski, R.L. Martin, K. Morokuma, V.G. Zakrzewski, G.A. Voth, P. Salvador, J.J. Dannenberg, S. Dapprich, A.D. Daniels, Ö. Farkas, J.B. Foresman, J.V. Ortiz, J. Cioslowski, D.J. Fox, Gaussian 09 (Gaussian, Inc., Wallingford CT, 2009). https://gaussian.com/glossary/g09/
[35] Dragon 3.0 Evaluation Version. Available online: http://www.disat.unimib.it/chm
[36] R. Sayyadi Kord Abadi, A. Alizadehdakhe, S. Dorani Shiraz. Russ. J. Phys. Chem. B 11 (2017) 307.
[37] https.//www.mathworks.com


[^0]:    *Corresponding author. E-mail: Sayyadi@iaurasht.ac.ir

